Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got

Published:2021-05-01 Issue:5 Volume:7 Page:677
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

West Howard (Jack)¹²,Gyawali Bishal³⁴⁵

Affiliation:

1. Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California

2. Web Editor, JAMA Oncology

3. Department of Oncology, Queen’s University, Kingston, Ontario, Canada

4. Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada

5. Division of Cancer Care and Epidemiology, Queen’s University, Kingston, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2775933/jamaoncology_west_2021_vp_200041_1621004914.49848.pdf

Reference8 articles.

1. Osimertinib in resected EGFR-mutated non–small-cell lung cancer.;Wu;N Engl J Med,2020

2. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.;Herbst;J Clin Oncol,2020

3. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.;Pignon;J Clin Oncol,2008

4. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) randomized trial.;Douillard;Int J Radiat Oncol Biol Phys,2008

5. CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.;Wu;J Clin Oncol,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons from ADAURA: Can we improve on a positive trial?;Cancer;2023-11-14

2. Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities;JCO Global Oncology;2023-09

3. Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives;Translational Lung Cancer Research;2023-04

4. Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients;Current Pharmaceutical Biotechnology;2023-03

5. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study;Clinical Lung Cancer;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3